# Atea Pharmaceuticals Inc. (AVIR) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $4.17, market value $334 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Atea Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 1.0×**. Each dollar of revenue is priced at 1.0×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 1.6×**. The shares trade at 1.6× book value; book value is a meaningful part of the valuation.

## Profitability
- **Operating margin: 39.4%**. 39.4% of revenue is left after running the business, an exceptional level.
- **Return on equity: -57.5%**. Return on equity is negative because earnings are negative.
- **Return on assets: 38.4%**. Each dollar of assets produces 38.4% of profit.

## Growth
- **EPS growth (1 yr): 3.0%**. Earnings per share rose 3.0%.

## Financial health
- **Current ratio: 7.82** (quick 7.82). Current assets cover the next year's liabilities 7.82 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Atea Pharmaceuticals Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 26.2%** (YTD 14.8%, 3-mo -11.1%). The shares are up 26.2% over twelve months including dividends.
- **From 52-week high: -35.3%** (45.3% above the low). Trading 35% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 32**. An RSI of 32 is neutral.
- **Beta (1 yr): 0.78** (volatility 51%). Beta of 0.78 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AVIR · Page: https://foliofundamentals.com/stocks/avir

Not investment advice.